drugset / Trial / NCT01211834
Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the efficacy and safety of tocilizumab vs placebo, in combination with stable, ongoing therapy, with regard to reduction in signs and symptoms in patients with moderate to severe active RA and inadequate response to current DMARD treatment
Timeline
- Start
- 2009-10
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Comparator | Azathioprine | Small molecule | — | — |
| Comparator | Chloroquine | Small molecule | — | — |
| Comparator | Hydroxychloroquine | Small molecule | — | — |
| Comparator | Leflunomide | Small molecule | — | — |
| Comparator | Methotrexate | Small molecule | — | — |
| Comparator | Sulfasalazine | Small molecule | — | — |